Does the media prefer PLSE or BBNX?

In the previous week, Beta Bionics had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Beta Bionics and 3 mentions for Pulse Biosciences. Beta Bionics' average media sentiment score of 0.44 beat Pulse Biosciences' score of 0.15 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LMAT or BBNX?

In the previous week, LeMaitre Vascular had 21 more articles in the media than Beta Bionics. MarketBeat recorded 29 mentions for LeMaitre Vascular and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat LeMaitre Vascular's score of 0.16 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AXGN or BBNX?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.79 -$15.70M -$0.68 N/A Beta Bionics $100.25M 6.24 -$73.20M -$1.65 N/A

Is AXGN or BBNX more profitable?

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Beta Bionics -61.31% -26.30% -23.25%

Does the media prefer AXGN or BBNX?

In the previous week, AxoGen had 18 more articles in the media than Beta Bionics. MarketBeat recorded 26 mentions for AxoGen and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat AxoGen's score of 0.11 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBNX or BFLY?

In the previous week, Butterfly Network had 10 more articles in the media than Beta Bionics. MarketBeat recorded 18 mentions for Butterfly Network and 8 mentions for Beta Bionics. Butterfly Network's average media sentiment score of 0.47 beat Beta Bionics' score of 0.44 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Butterfly Network 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ATRC or BBNX?

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 3.74 -$11.45M $0.21 187.33 Beta Bionics $100.25M 6.24 -$73.20M -$1.65 N/A

Is ATRC or BBNX more profitable?

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Beta Bionics -61.31% -26.30% -23.25%

Does the media refer more to ATRC or BBNX?

In the previous week, AtriCure had 9 more articles in the media than Beta Bionics. MarketBeat recorded 17 mentions for AtriCure and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat AtriCure's score of 0.42 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Beta Bionics (BBNX) Competitors

$13.91 -0.66 (-4.53%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$13.92 +0.02 (+0.11%)

As of 08/5/2026 07:34 PM Eastern

Compare

BBNX vs. PLSE, LMAT, AXGN, BFLY, and ATRC

Should you buy Beta Bionics stock or one of its competitors? MarketBeat compares Beta Bionics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beta Bionics include Pulse Biosciences (PLSE), LeMaitre Vascular (LMAT), AxoGen (AXGN), Butterfly Network (BFLY), and AtriCure (ATRC). These companies are all part of the "healthcare equipment" industry.

How does Beta Bionics compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pulse Biosciences has higher earnings, but lower revenue than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	7,494.45	-$72.78M	-$1.10	N/A
Beta Bionics	$100.25M	6.24	-$73.20M	-$1.65	N/A

In the previous week, Beta Bionics had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Beta Bionics and 3 mentions for Pulse Biosciences. Beta Bionics' average media sentiment score of 0.44 beat Pulse Biosciences' score of 0.15 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulse Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, indicating that its share price is 213% more volatile than the broader market.

Pulse Biosciences presently has a consensus target price of $32.33, indicating a potential downside of 14.69%. Beta Bionics has a consensus target price of $20.10, indicating a potential upside of 44.50%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Pulse Biosciences has a net margin of 0.00% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Beta Bionics	-61.31%	-26.30%	-23.25%

Summary

Beta Bionics beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

LeMaitre Vascular has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to Beta Bionics' net margin of -61.31%. LeMaitre Vascular's return on equity of 15.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.90%	10.17%
Beta Bionics	-61.31%	-26.30%	-23.25%

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.23	$57.73M	$2.71	29.15
Beta Bionics	$100.25M	6.24	-$73.20M	-$1.65	N/A

LeMaitre Vascular currently has a consensus target price of $110.60, indicating a potential upside of 40.00%. Beta Bionics has a consensus target price of $20.10, indicating a potential upside of 44.50%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts clearly believe Beta Bionics is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, LeMaitre Vascular had 21 more articles in the media than Beta Bionics. MarketBeat recorded 29 mentions for LeMaitre Vascular and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat LeMaitre Vascular's score of 0.16 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LeMaitre Vascular beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

AxoGen currently has a consensus price target of $51.00, indicating a potential upside of 12.78%. Beta Bionics has a consensus price target of $20.10, indicating a potential upside of 44.50%. Given Beta Bionics' higher possible upside, analysts clearly believe Beta Bionics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AxoGen has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market.

In the previous week, AxoGen had 18 more articles in the media than Beta Bionics. MarketBeat recorded 26 mentions for AxoGen and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat AxoGen's score of 0.11 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Beta Bionics	-61.31%	-26.30%	-23.25%

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.79	-$15.70M	-$0.68	N/A
Beta Bionics	$100.25M	6.24	-$73.20M	-$1.65	N/A

Summary

AxoGen beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to Butterfly Network?

Beta Bionics (NASDAQ:BBNX) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Beta Bionics has a net margin of -61.31% compared to Butterfly Network's net margin of -66.74%. Beta Bionics' return on equity of -26.30% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Butterfly Network	-66.74%	-33.99%	-22.96%

37.9% of Butterfly Network shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beta Bionics has a beta of 3.13, indicating that its share price is 213% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Beta Bionics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	6.24	-$73.20M	-$1.65	N/A
Butterfly Network	$97.61M	21.96	-$77.06M	-$0.29	N/A

In the previous week, Butterfly Network had 10 more articles in the media than Beta Bionics. MarketBeat recorded 18 mentions for Butterfly Network and 8 mentions for Beta Bionics. Butterfly Network's average media sentiment score of 0.47 beat Beta Bionics' score of 0.44 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Butterfly Network	6 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Beta Bionics presently has a consensus price target of $20.10, indicating a potential upside of 44.50%. Butterfly Network has a consensus price target of $5.56, indicating a potential downside of 33.92%. Given Beta Bionics' stronger consensus rating and higher probable upside, research analysts clearly believe Beta Bionics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Beta Bionics beats Butterfly Network on 9 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

AtriCure presently has a consensus price target of $48.50, indicating a potential upside of 23.28%. Beta Bionics has a consensus price target of $20.10, indicating a potential upside of 44.50%. Given Beta Bionics' higher probable upside, analysts plainly believe Beta Bionics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

AtriCure has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.13, suggesting that its stock price is 213% more volatile than the broader market.

In the previous week, AtriCure had 9 more articles in the media than Beta Bionics. MarketBeat recorded 17 mentions for AtriCure and 8 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.44 beat AtriCure's score of 0.42 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	3.74	-$11.45M	$0.21	187.33
Beta Bionics	$100.25M	6.24	-$73.20M	-$1.65	N/A

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Beta Bionics	-61.31%	-26.30%	-23.25%

Summary

AtriCure beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$655.50M	$5.80B	$6.86B	$12.98B
Dividend Yield	N/A	1.78%	2.60%	9.79%
P/E Ratio	-8.43	23.50	280.40	25.25
Price / Sales	6.24	58.73	562.13	77.61
Price / Cash	N/A	32.67	71.79	50.79
Price / Book	2.44	6.12	12.94	6.09
Net Income	-$73.20M	$151.74M	$3.49B	$347.95M
7 Day Performance	-2.52%	3.51%	2.42%	3.11%
1 Month Performance	-16.81%	-1.62%	-2.87%	-2.99%
1 Year Performance	-8.49%	8.95%	75.29%	20.51%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	2.7269 of 5 stars	$13.91 -4.5%	$20.10 +44.5%	-12.0%	$655.50M	$100.25M	N/A	294	Positive News
PLSE Pulse Biosciences	1.4127 of 5 stars	$35.13 +0.3%	$32.33 -8.0%	+148.5%	$2.43B	$350K	N/A	140
LMAT LeMaitre Vascular	4.6497 of 5 stars	$101.32 -0.9%	$112.60 +11.1%	-7.7%	$2.34B	$249.60M	37.39	490	Trending News Earnings Report Analyst Downgrade Gap Down
AXGN AxoGen	2.4055 of 5 stars	$42.21 +2.1%	$51.00 +20.8%	+229.6%	$2.22B	$225.21M	N/A	450	Trending News Analyst Revision
BFLY Butterfly Network	1.2241 of 5 stars	$7.08 -13.3%	$5.56 -21.5%	+525.9%	$2.08B	$97.61M	N/A	460	Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, LMAT, AXGN, BFLY, and ATRC

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Summary

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Butterfly Network?

Summary

How does Beta Bionics compare to AtriCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, LMAT, AXGN, BFLY, and ATRC

How does Beta Bionics compare to Pulse Biosciences?

Do insiders and institutionals believe in PLSE or BBNX?

Which has higher valuation & earnings, PLSE or BBNX?

Does the media prefer PLSE or BBNX?

Which has more risk and volatility, PLSE or BBNX?

Do analysts recommend PLSE or BBNX?

Is PLSE or BBNX more profitable?

Summary

How does Beta Bionics compare to LeMaitre Vascular?

Which has more volatility and risk, LMAT or BBNX?

Is LMAT or BBNX more profitable?

Do institutionals and insiders hold more shares of LMAT or BBNX?

Which has stronger valuation & earnings, LMAT or BBNX?

Do analysts rate LMAT or BBNX?

Does the media refer more to LMAT or BBNX?

Summary

How does Beta Bionics compare to AxoGen?

Do analysts recommend AXGN or BBNX?

Do institutionals & insiders believe in AXGN or BBNX?

Which has more risk and volatility, AXGN or BBNX?

Does the media prefer AXGN or BBNX?

Is AXGN or BBNX more profitable?

Which has higher earnings & valuation, AXGN or BBNX?

Summary

How does Beta Bionics compare to Butterfly Network?

Is BBNX or BFLY more profitable?

Do institutionals and insiders believe in BBNX or BFLY?

Which has more volatility and risk, BBNX or BFLY?

Which has better valuation & earnings, BBNX or BFLY?

Does the media refer more to BBNX or BFLY?

Do analysts rate BBNX or BFLY?

Summary

How does Beta Bionics compare to AtriCure?

Do analysts rate ATRC or BBNX?

Which has more risk and volatility, ATRC or BBNX?

Does the media refer more to ATRC or BBNX?

Which has preferable valuation and earnings, ATRC or BBNX?

Do institutionals and insiders believe in ATRC or BBNX?

Is ATRC or BBNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools